

CONTENTS

<i>Contributors</i>	<i>xv</i>
<i>Preface</i>	<i>xxi</i>
1. Enzymatic Formation of Anandamide	1
Yasuo Okamoto, Kazuhito Tsuboi, and Natsuo Ueda	
I. The Transacylation–Phosphodiesterase Pathway for Anandamide Formation	2
II. NAT	4
III. NAPE-PLD	9
IV. Alternative Pathways Forming NAEs from NAPEs	15
V. Conclusions	18
References	19
2. Organized Trafficking of Anandamide and Related Lipids	25
Marla L. Yates and Eric L. Barker	
I. AEA and the Endocannabinoid System	26
II. AEA Transport	31
Acknowledgment	45
References	45
3. Biosynthesis of Oleamide	55
Gregory P. Mueller and William J. Driscoll	
I. Introduction	56
II. Fatty Acid Amide Messengers: Structural Considerations	56
III. Natural Occurrence of Oleamide	57
IV. Biologic Actions of Oleamide	58
V. Proposed Mechanisms for the Biosynthesis of Oleamide	59
VI. Oleamide Biosynthesis by Peptidylglycine Alpha-amidating Monoxygenase	60
VII. Discovery of Cytochrome <i>c</i> as an Oleamide Synthase	62
VIII. Cytochrome <i>c</i> also Catalyzes the Formation of Oleoylglycine and Other Long-Chain Fatty Acylamino Acids	64
IX. Proposal for an Oleamide Synthesome	66

X. Apoptosis: A Model for the Mechanism and Regulation of Oleamide Biosynthesis	67
XI. Considerations for the Investigation of Oleamide Biosynthesis	70
XII. Future Directions and Concluding Remarks	70
References	71
4. Anandamide Receptor Signal Transduction	79
Catherine E. Goodfellow and Michelle Glass	
I. Introduction	80
II. Cannabinoid Receptor 1	81
III. Cannabinoid Receptor 2	89
IV. Transient Receptor Potential Vanilloid 1	90
V. Evidence for Additional Receptors	92
VI. Concluding Remarks	98
References	99
5. Is GPR55 an Anandamide Receptor?	111
Andrew J. Brown and C. Robin Hiley	
I. Δ^9 -Tetrahydrocannabinol, CB ₁ , and CB ₂ Receptors	112
II. Functional Evidence for Novel Cannabinoid Receptors	113
III. Genomics of G Protein-Coupled Cannabinoid Receptors	116
IV. The Orphan Receptor GPR55	117
V. Endogenous Ligands for GPR55	121
VI. GPR55 Cellular Signaling Pathways	123
VII. Interactions Between GPR55 and CB ₁ Receptors	126
VIII. Conclusion: GPR55 as an Anandamide Receptor	128
References	133
6. The Endocannabinoid System During Development: Emphasis on Perinatal Events and Delayed Effects	139
Ester Fride, Nikolai Gobshtis, Hodaya Dahan, Aron Weller, Andrea Giuffrida, and Shimon Ben-Shabat	
I. Introduction	140
II. Early Gestation	141
III. Neural Development	146
IV. Postnatal Development	147
V. Effects of Developmental Manipulation of the ECS System on the Offspring	150
VI. Conclusions	152
Acknowledgments	153
References	153

7. Cannabinoid Receptor CB₁ Antagonists: State of the Art and Challenges	159
Maurizio Bifulco, Antonietta Santoro, Chiara Laezza, and Anna Maria Malfitano	
I. Introduction	160
II. Endocannabinoid System: Control of Energy Balance	161
III. Cannabinoid CB ₁ Receptors and CB ₁ Antagonists	162
IV. CB ₁ Antagonists in the Treatment of Obesity and Related Comorbidities	169
V. Other Emerging Effects of CB ₁ Antagonists	176
VI. Therapeutic Prospects	179
VII. Conclusions	180
Acknowledgments	181
References	181
8. Novel Endogenous <i>N</i>-Acyl Glycines: Identification and Characterization	191
Heather B. Bradshaw, Neta Rimmerman, Sherry S.-J. Hu, Sumner Burstein, and J. Michael Walker	
I. Historical View of Lipid Signaling Discoveries	192
II. The Identification of Endogenous Signaling Lipids with Cannabimimetic Activity	192
III. Identification of Additional <i>N</i> -Acyl Amides	193
IV. <i>N</i> -Arachidonoyl Glycine Biological Activity	194
V. <i>N</i> -Arachidonoyl Glycine Biosynthesis	194
VI. <i>N</i> -Palmitoyl Glycine Biological Activity	195
VII. <i>N</i> -Palmitoyl Glycine Biosynthesis	197
VIII. PalGly Metabolism	197
IX. Identification and Characterization of Additional Members of the <i>N</i> -Acyl Glycines	198
X. Biological Activity of Novel <i>N</i> -Acyl Glycines	200
XI. Conclusions	201
References	203
9. The Endocannabinoid Anandamide: From Immunomodulation to Neuroprotection. Implications for Multiple Sclerosis	207
Fernando G. Correa, Leyre Mestre, Fabián Docagne, José Borrell, and Carmen Guaza	
I. Introduction	208
II. AEA as a Neuroimmune Signal	212

III. Anandamide and Multiple Sclerosis	219
IV. Concluding Remarks	223
Acknowledgment	224
References	224
10. Modulation of the Endocannabinoid-Degrading Enzyme Fatty Acid Amide Hydrolase by Follicle-Stimulating Hormone	231
Paola Grimaldi, Gianna Rossi, Giuseppina Catanzaro, and Mauro Maccarrone	
I. Follicle-Stimulating Hormone: Signal Transduction and Molecular Targets	232
II. Sertoli Cells: Activities and Biological Relevance	237
III. Overview of the Endocannabinoid System	239
IV. The ECS in Sertoli Cells	241
V. Regulation of FAAH by FSH in Sertoli Cells	243
VI. FAAH Is an Integrator of Fertility Signals	244
VII. Conclusions	254
Acknowledgments	255
References	255
11. Glucocorticoid-Regulated Crosstalk Between Arachidonic Acid and Endocannabinoid Biochemical Pathways Coordinates Cognitive-, Neuroimmune-, and Energy Homeostasis-Related Adaptations to Stress	263
Renato Malcher-Lopes and Marcelo Buzzi	
I. Introduction	264
II. The Arachidonic Acid Cascade	266
III. Glucocorticoid-Mediated Inhibition of cPLA ₂ -Dependent AA Release from Membrane Phospholipids	269
IV. Biosynthesis of the AA-Containing Endocannabinoids AEA and 2-AG	271
V. Nongenomic Glucocorticoid-Induced Activation of Endocannabinoid Biosynthesis	274
VI. Endocannabinoids Metabolization	278
VII. Crosstalk Between GCs and COX ₂ in the Control of Neuroinflammation and Neuroprotection	282
VIII. Crosstalk Between GCs and COX ₂ in the Control of Synaptic Plasticity and Learning Processes	285
IX. Coordination of GC-Mediated Control of the Neuroimmune Response and Energy Homeostasis Control	288
Acknowledgments	295
References	295

12. Modulation of the Cys-Loop Ligand-Gated Ion Channels by Fatty Acid and Cannabinoids	315
Li Zhang and Wei Xiong	
I. CB Receptor-Dependent and -Independent Effects of Endocannabinoids	316
II. Structure and Function of the Cys-Loop LGICs	317
III. Inhibition of 5-HT ₃ Receptors by Cannabinoids	318
IV. Modulation of Gly Receptor Function by Cannabinoids	324
V. Inhibition of nACh Receptors by Endocannabinoids	328
VI. Modulation of GABA _A Receptor Function by Fatty Acids	329
VII. Concluding Discussion	330
References	331
13. Endogenous Cannabinoids and Neutrophil Chemotaxis	337
Douglas McHugh and Ruth A. Ross	
I. Cellular Motility and Neutrophils	338
II. The Endogenous Cannabinoid System	339
III. Cannabinoids Modulate Cell Migration	342
IV. Endocannabinoid Effects on Basal Locomotion of Neutrophils	343
V. Endocannabinoid Effects on Induced Migration of Neutrophils	343
VI. Cannabinoid Receptor Expression in Neutrophils	344
VII. Inhibition of Induced Migration: Which Receptors are Involved?	345
VIII. Inhibitory Signal Transduction Mechanisms: Receptor Crosstalk	350
IX. Inhibitory Signal Transduction Mechanisms: Disruption of the Actin Cytoskeleton	351
X. Conclusion	356
References	357
14. CB₁ Activity in Male Reproduction: Mammalian and Nonmammalian Animal Models	367
Riccardo Pierantoni, Gilda Cobellis, Rosaria Meccariello, Giovanna Cacciola, Rosanna Chianese, Teresa Chioccarelli, and Silvia Fasano	
I. Introduction	368
II. Receptor Properties	368
III. Brain–Pituitary Axis	371
IV. Testis	374
V. Excurrent Duct System	379
VI. Concluding Remarks	382
References	382

15. Anandamide and the Vanilloid Receptor (TRPV₁)	389
Attila Tóth, Peter M. Blumberg, and Judit Boczán	
I. Cannabinoid and Vanilloid Receptors	390
II. Biochemistry of Anandamide	392
III. Anandamide as Vanilloid Receptor (TRPV ₁) Ligand	396
IV. Other Anandamide Receptors	404
V. Physiological Actions of Anandamide on TRPV ₁	404
VI. Future Directions	410
References	411
16. Endocannabinoid System and Fear Conditioning	421
Leonardo B. M. Resstel, Fabrício A. Moreira, and Francisco S. Guimarães	
I. Introduction	421
II. Fear Conditioning	423
III. Influence of Endocannabinoids on Fear Conditioning	426
IV. Brain Regions in which Endocannabinoids may Modulate Fear Conditioning	429
V. Conclusion	433
References	433
17. Regulation of Gene Transcription and Keratinocyte Differentiation by Anandamide	441
Nicoletta Pasquariello, Sergio Oddi, Marinella Malaponti, and Mauro Maccarrone	
I. Introduction	442
II. Epidermis	445
III. Transcriptional Control of Skin Differentiation	453
IV. Endocannabinoid System in Epidermis	455
V. Modulation of the Endocannabinoid System in Differentiating Keratinocytes	456
VI. Repression of Gene Transcription by Anandamide	457
VII. Conclusions	459
Acknowledgments	460
References	461
18. Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer	469
Gianfranco Alpini and Sharon DeMorrow	
I. Introduction	470
II. Changes in the Endocannabinoid System in Cancer	471

III. Antiproliferative Effects of Anandamide	473
IV. Effects of AEA on Migration, Invasion, and Angiogenesis	476
V. Targeting Degradation Enzymes of Cannabinoids as an Anticancer Therapy	479
VI. Tumor Promoting Effects of Anandamide	480
VII. Conclusions	480
Acknowledgments	481
References	481
19. Use of Cannabinoids as a Novel Therapeutic Modality Against Autoimmune Hepatitis	487
Rupal Pandey, Venkatesh L. Hegde, Narendra P. Singh, Lorne Hofseth, Uday Singh, Swapan Ray, Mitzi Nagarkatti, and Prakash S. Nagarkatti	
I. Introduction	488
II. The Endogenous Cannabinoid System	489
III. The Biosynthesis of Endocannabinoids	490
IV. Endocannabinoid System is Autoprotective	490
V. Autoimmune Hepatitis	492
VI. Treatment Drawbacks	494
VII. Cannabinoid/Endocannabinoid System in Hepatitis	494
VIII. Conclusions and Future Directions	499
Acknowledgments	500
References	500
<i>Index</i>	505